Xá cđ nh mit ng quan gi as methyl hóa gen p16INK4 vƠ b nh ungth

Một phần của tài liệu KHẢO SÁT TÌNH TRẠNG METHYL HÓA GEN p76/XK“2 TẠI CÁC ĐẢO CpG THUỘC VÙNG PROMOTER TRÊN MỘT SÓ BỆNH UNG THƯ (Trang 69 - 84)

3.3. KT QU T HC NGH IM

3.3.5. Xá cđ nh mit ng quan gi as methyl hóa gen p16INK4 vƠ b nh ungth

Ghi chú: m u mô vú c a các b nh nhơn tu i nh h n 40, t 40 - 50 vƠ cao h n tu i 50 l n l t lƠ N1, N2, N3. M u môvú trong giai đo n I, II, III vƠ IV.

3.3.5. Xác đnh m i t ng quan gi a s methyl hóa gen p16INK4 b nh ung th th

K t qu ghi nh n trên m u b nh ung th vú vƠ m u mơ lƠnh tính đ c x lỦ th ng kê, nh m tính tốn m i t ng quan gi a t l methyl hóa t i vùng promoter gen p16INK4v i b nhung th vú.

M t cách t ng quát, tính tốn đ u tiên v i hai phơn nhómμ nhóm m u b nh (ung th ) vƠ nhóm m u lƠnh (v i ung th nh ng m c b nh khác v vú).

Nhóm m u b nh lƠ sinh thi t mô đ c thu nh n t b nh vi n H Y D c Tp. HCM. M t s ch tiêu đánh giá tính ch t c a b nh (ung th vú) d a trên đ c đi m b nh h c bao g mμ giai đo n b nh (t giai đo n I đ n giai đo n IV).

Nhóm m u lƠnh (v i ung th ) nh ng m c các b nh lỦ khác v vú (kèm theo ch đ nh ph u thu t l y sinh thi t mô vú c a các bác s .

K t qu th ng kê cho th y tính ch t methyl hóa t i các v trí CpG vùng promoter gen p16INK4đ c kh o sát trong nghiên c u nƠy lƠ m t đ c tr ng c a b nh ung th vú, (đ c trình bƠy B ng 3.14, B ng ph l c 1).

B ng 3.14. M i t ng quan gi a t l methyl hóa t i vùng promoter gen p16INK4 v i ung th vú

Lo i m u p16

INK4 Giá tr p*

Không methyl Methyl T ng M u lƠnh 2 (66,67%) 1 (33,33%) 3 (30%) M u ung th

vú 3 (42,86%) 4 (57,14%) 7 (70%)

4 (40,0%) 6 (60%) 10 (100%) p = 0,6726 p* > 0,05,  Th ng kê b ng ph n m m Medcal(B , 2014)

Phơn tích chi ti t h n đ i v i các ch tiêu c n lơm sƠng (tu i) vƠ lơm sƠng (các đ c đi m mô b nh) nh m xác đ nh m i t ng quan gi a tính ch t methyl hóa v i ung th vú, ti n hƠnh ghi nh n các k t qu sau (B ng 3.14, B ng ph l c 2).

Lý Th Tuy t Ng c Trang 59

B ng 3.15. M i t ng quan gi a t l methyl hóa t i vùng promoter gen p16INK4v i các y u t lơm sƠng trên b nh nhơn ung th vú

Nhóm tu i

M u b nh

Methyl p16INK4 Không methyl p16INK4 N1 (<40) 3 (50,0%) 1 (25,0%) N2 (40 - 50) 2 (33,3%) 1 (25,0%) N3 (>50) 1 (16,7%) 2 (50,0%) Giá tr p* 0,5241 Giai đo n b nh I 2 (50%) 0 (0%) II 2 (50%) 1 (33,3%) III 0 (0%) 1 (33,3%) IV 0 (0%) 1 (33,3%) Giá tr p* 0,2330 p* > 0,05,  Th ng kê b ng ph n m m Medcal(B , 2014)

Ghi chúμ m u mô vú c a các b nh nhơn tu i nh h n 40, t 40 - 50 vƠ cao h n tu i 50 l n l t lƠ N1, N2, N3. M u mô vú trong giai đo n I, II, III, IV.

i v i y u t ắnhóm tu i” c a các b nh nhơn đ c nghiên c uμ Nhóm b nh nhơn N1 (có đ tu i < 40) chi m t l ph n tr m cao nh t trong các nhóm tu i kho ng 50,0% , đi u nƠy ch ng t nguy c ung th vú tr c giai đo n ti n mƣn kinh. Phơn tích th ng kê, cho th y y u t nhóm tu i vƠ m c đ methyl hóa gen p16INK4 khơng có s khác bi t có Ủ ngh a khi giá tr p - value b ng 0,5241 cao h n 0,05 (đ c trình bƠy B ng 3.14, B ng ph l c 2).

i v i y u t ắgiai đo n” ung th μ s li u đ c trình bƠi B ng 3.14, B ng ph l c 3, nh n th y trong các giai đo n ung th vú, m c đ methyl hóa trong giai đo n I, II có ph n tr m cao nh t chi m kho ng > 50,0% hay nói cách khác methyl hóa đ c bi u hi n s m trong quá trình sinh u vƠ q trình b nh hóa c a ung th vú. Tuy nhiên, giá tr p - value đ t 0,2330 cao h n 0,05 nên th ng kê khơng có Ủ ngh a.

Lý Th Tuy t Ng c Trang 60

3.3.5. Kh o sát m c đ liên quan (t su t chênh - Odd ratio - OR nguy c t ngđ i - relative risk - RR) gi a tính ch t methyl hóa v i ung th

T su t chênh (Odd ratio) vƠ y u t nguy c t ng đ i (ralative Risk) dùng đ đánh giá hay đo l ng m c đ m nh y u c a m i liên quan m c đ methyl hóa v i lo i m u ung th vú (m u lƠnh vƠ m u ung th ).

K t qu th ng kê cho th y, t su t chênh (OR = 2,6667) vƠ y u t nguy c (RR = 2,0000) có giá tr p - value l n l t lƠ 0,4968; 0,5087 v i p > 0,05 khơng có s khác bi t trong th ng kê. Nguyên nhơn lƠ s m u nghiên c u còn h n h p, n u t ng s l ng m uung th vú có kh n ng th hi n đ c s t ng quan v m c đ methyl hóa v i các lo i m u (m u lƠnh vƠ m u ung th ).

B ng 3.16. M c đ liên quan gi a tính ch t methyl hóa t i vùng promoter gen p16INK4v i ung th vú

Lo i m u p16

INK4 Giá tr p*

Không methyl Methyl T ng

M u lƠnh 2 (66,67%) 1 (33,33%) 3 (30%) M u ung th vú 3 (42,86%) 4 (57,17%) 7 (70%) 4 (40,0%) 6 (60%) 10 (100%) p* = 0,6726 T su t chênh (OR) 2,6667 0,4968 T s nguy c (RR) 2,0000 0,5087 p* > 0,05,  Th ng kê b ng ph n m m Medcal (B, 2014)

Lý Th Tuy t Ng c Trang 61

4.1. K T LU N

Thu th p thơng tin, xác đ nh v trí vƠ mơ t c u trúc vùng promoter, các đ o CpG vƠ exon 1 thu c gen p16INK4a.

Th ng kê t n s methyl hóa gen p16INK4 trên các m u ung th vú, ung th c t cung, ung th ph i, ung th đ i tr c trƠng l n l t lƠ 52,5%, 68,28%, 3λ,6λ%, 83,02% trong t ng s 24 cơng trình nghiên c u đ c cơng b trên th gi i.

Kh o sát vƠ đánh giá t n s methyl hóa gen p16INK4 trên 10 m u mô vú đ c đúc paraffin Vi t Nam. T n s methyl hóa các t bƠo ung th , m u lƠnh l n l t lƠ 57,14%, 33,33% đ ng th i xác đ nh m i t ng gi a t l methyl hóa t i vùng promoter gen p16INK4v i các y u t lơm sƠng trên b nh nhơn ung th vú trong đ tu i nh h n 40 (50%) hay giai đo n I (50%) vƠ II (50%). T s OR (t su t chênh - Odd ratio - OR) đ t 2,6667 vƠ t s RR (nguy c t ng đ i - relative risk) đ t 2,0000.

4.2. NGH

Kh o sát th c nghi m gen p16INK4 trên nhi u b nh ung th , t ng c ng c m u kh o sát tình tr ng methyl hóa m u ung th Vi t Nam.

Ti p t c ti n hƠnh th c nghi m kh o sát tính ch t methyl hóa k t h p v i các ghi chúv phơn lo i mô h c đ đánh giá kh n ng s d ng tính ch t methyl hóa nƠy nh m t d u ch ng sinh h c (Bio - marker) h u hi u cho b nh ung th vú Vi t Nam.

Lý Th Tuy t Ng c Trang 62

TÀI LI U THAM KH O

Ti ng Vi t

[1]. Lê Th Trúc Linh, H B o Khuyên, Lê Huy n Ễi Thúy (2010), Xơy d ng quy trình Methylation specific PCR nh m kh o sát m c đ methyl hóa t i các đ o CpG thu c vùng promoter hai gen Trail - R3, Trail - R4 trên các b nh nhơn b ung th c t cung, T p chí Cơng ngh

sinh h c, 8(3B), tr. 1091 ậ 1096.

Ti ng Anh

[2]. AS B. (1999), Blood , 5(94), pp. 1773 - 1781.

[3]. Baker D.J. (2008), Opposing roles for p16INK4 and p19Arf in senescence and ageing caused by BubR1 insufficiency, Nat Cell Biol, 10(7), pp. 825 - 836.

[4]. Bean G.R. (2007), Morphologically normal - appearing mammary epithelial cells obtained from high - risk women exhibit methylation silencing of INK4a/ARF, Clin Cancer Res, 13(22), pp. 6834 - 6841. [5]. Bearzatto A. (2002), Hypermethylation p16INK4 detected by

Fluorescent Methylation - Specific PCR in plasmas from non - small cell lung cancer, Clin Cancer Res, 3782 (8), pp. 3782 - 3787.

[6]. Carestiato F. N. (2013), An upward trend in DNA p16INK4 methylation pattern and high risk HPV infection according to the severity of the cervicial lesion, Rev Inst. Med. Trop. Sao Paulo, 55(5), pp. 329 - 334.

[7]. Choi B. Y. (2005), The tumor suppressor p16INK4 prevents cell transformation through inhibition of c - Jun phosphorylation and AP - 1 activity, Nature Structural and Molecular Biology Cell Biol., 12, pp. 699 - 707.

Lý Th Tuy t Ng c Trang 63 [8]. Coleman K.G. (1997), Identification of CDK4 sequences involved

in cyclin D1 and p16 binding, J Biol Chem, 272(30), pp. 18869 - 18874.

[9]. Cutts F.T. (2007), Humanpapillo virus and HPV vaccines: a review, Bulletin of the World Health Organization.

[10]. Das P.M. (2004), DNA methylation and cancer, Journal of Clinical Oncology, 22(22), pp. 4632 - 4642.

[11]. Deep J. S. (2012), Aberrant methylation in promoters of GSTP1, p16, p14 and RASSF1A genes in smokers of North India, International Scholarly Research Network ISRN Pulmonology, ID 247631, pp. 1 - 6. [12]. Delpu Y. (2013), DNA methylation and cancer diagnosis, Int. J.

Molecular Sciences, 14(7), pp. 15029 - 15058.

[13]. Herman J.G. (1996), Methylation - specific PCR: A novel PCR assay for methylation status of CpG islands, Medical Sciences, 93, pp. 9821 - 9826.

[14]. Hibi K. (2001), Mitochondrial DNA alteration in esophageal cancer, International Journal of Cancer, 92(3), pp. 319 - 321.

[15]. Lee J.J. (2012), Tumor suppressor gene in primary breast cancer tissue and their quantitative p16INK4 hypermethylation in plasma by Real - Time PCR, The Korean Journal of Pathology, 46, pp. 554 - 561. [16]. Hu X.C. (2003), Tumor - derived aberrant methylation in plasma of

invasive ductal breast cancer patients: clinical implications, Oncol. Rep., 10(6),pp. 1811 - 1815.

[17]. Jha A. K. (2012), p16INK4 and p15INK4 gene promoter methylation in cervical cancer patients, Oncology Letters, 3, pp. 1331 - 1335.

[18]. Janzen V. (2006), Stem - cell ageing modified by the cyclin - dependent kinase inhibitor p16INK4, Nature, 443, pp. 421 - 426.

[19]. Jarmalaite S. (2003), Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer,

Lý Th Tuy t Ng c Trang 64 Iternational Journal of Cancer,106(6), pp. 913 - 918.

[20]. Jemal A. (2011), Global cancer statistics, CA Cancer J Clin, 61(2), pp. 69 - 90.

[21]. Jennifer B. (2009), Promoter methylation and the detection of breast cancer, Cancer causes control, 20(9), pp. 1539 - 1550.

[22]. Jie G. (2007), Relationship between expression and methylation status of p16INK4 and the proliferative activity odifferent areas' tumour cells in human colorectal cancer, Int J Clin Pract, 61(9), pp. 1523 - 1529.

[23]. Jing F. (2007), Hypermethylation of tumor suppressor genes BRCA1,p16 and 14 - 3 - 3sigma in serum of sporadic breast cancer patients, Onkologie, 30(1 - 2), pp. 14 - 19.

[24]. Kamb A. (1994), A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264(5157), pp. 436 - 440.

[25]. Kim N.B. (2005), Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues, Internationa Journal of Oncology, 2, pp. 1217 - 1226.

[26]. Jane B.R. (2011), The cell cycle, Campell biology, Chapter 12. [27]. Kim W.Y. (2006), The regulation of INK4/ARF in cancer and

aging, Cell, 127(2), pp. 265 - 275.

[28]. Kim, Y.T. and M. Zhao (2005), Aberrant cell cycle regulation in cervical carcinoma, Yonsei Medical, 46(5), pp. 597 - 613.

[29]. Krishnamurthy J. (2004), INK4/ Arf expression is a Bio - marker of aging, J Clin Invest, 114, pp. 1299 - 1307.

[30]. Laird, P.W. (2003), The power and the promise of DNA methylation markers, Nature Publishing Group, 3.

[31]. Latest world cancer statistics Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed, (2013), International Agency for Research on Cancer.

Lý Th Tuy t Ng c Trang 65 [32]. Le T.T.L., Ho T.B.P., Ton N.T.K., Doan T.P.T, Le H.A.T. (2011),

Appraisal of potential methylation Bio - markers: BRCA1, p16INK4, cyclin D2, GSTP1, RASSF1A in breast cancer early detection, Journal of Science and Technology, 49(1A), pp. 329 - 337.

[33]. Li J. (2002), Novel insights into the INK4 - CDK4/6 - Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4 - mediated phosphorylation of Rb, Biochemistry, 41, pp. 3977 - 3983. [34]. Li J. (2011), The Regulatory Mechanisms of Tumor Suppressor

p16INK4 and Relevance to Cancer, Biochemistry, 25(50), pp. 5566 - 5582.

[35]. Liggett W.H. (1998), Role of the p16 Tumor Suppressor Gene in Cancer, Jounnal of Clinical Oncology, (16)3, pp. 1197 - 1206.

[36]. Lo P. K. (2008), Epigenomics and breast cancer, Pharmacogenomics, (9)12, pp. 1879 - 1902.

[37]. LoF - Ohlin Z.M. (2011), Hypermethylation of promoter regions of the APC1A and p16INK4genes in relation to prognosis and tumor characteristics in cervical cancer, International Journal of Oncology, 39, pp. 683 - 688.

[38]. Lu Q. (2012), DNA methylation changes in cervicial cancer, Cancer Epignetics Method in Molecular Biology, 863, pp. 155 - 176. [39]. Malhotra P. (2010), Aberrant promoter methylation of p16 in

colorectal adenocarcinoma in North Indian patients, World J Gastrointest Oncol, 2(7), pp. 295 - 303.

[40]. Man J.H. (2010), Gankyrin plays an essential role in Ras - induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells, J Clin Invest, 120, pp. 2829 - 2841.

[41]. Marcus W. K. (2013), Epigenetic changes in patients with multiple sclerosis, Nature Reviews Neurology ,9, pp. 35 - 43.

Lý Th Tuy t Ng c Trang 66 hypermethylome, Human Molecular Genetics, 16(1), pp. 50 - 59.

[43]. Matouk Charles C. (2008), Epigenetic Regulation of Vascular Endothelial Gene Expression, Circulation Research, 102(8), pp. 873 - 887.

[44]. Mohammed A. (2009), Status of p16INK4 and E - Cadheringene promoter methylation in Moroccan patients with cervical carcinoma, Oncology Research, 18, pp. 1 - 100 .

[45]. Molofsky AV. (2006), Increasing p16INK4 expression decreases forebrain progenitors and neurogenesis during aging, Nature, 443(7110), pp. 448 - 452.

[46]. Nakayama G. (2007), p16 Methylation in Serum as a potential marker for the malignancy of colorectal carcinoma, Anticancer Reasearch, 27 (5A), pp. 3367 - 3370.

[47]. Nephew K.P. (2002), Epigenetic gene silencing in cancer initiation and progression, Cancer Letters, 190(2), pp. 125 - 133.

[48]. Nguyen H.L. (2010), Cost of treatment for breast cancer in central Vietnam, Glob Health Action, 6: 18872.

[49]. Ono A. (2011), Epigenetic aberrant hypermethylation of DNA in endometrial cancer: application as a Bio - marker, Journal of Cancer Therapy, 2, pp. 610 - 615.

[50]. Lamy A. (2002), Aberant methylation of the CDKN2A/p16 gene promoter regionon prevasive bronchial leison: aprospectives study in high - SK patients without invasive cancer, Int. J. Cancer, 100(2), pp. 189 - 193.

[51]. Ota N. (2006), Prognostic significance of hypermethylation p16INK4 in non - small cell lung cancer is evident by quantitative DNA methylation analysis, Anticancer Research, 26, pp. 3729 - 3732.

[52]. Peter B., World cancer Report 2008 [online], WHO press, The International Agency for Research Cancer (IARC).

Lý Th Tuy t Ng c Trang 67 [53]. Portela A. (2010), Epigenetic modifications and human disease,

Nature biotechnology, 28(10), pp. 1057 - 1067.

[54]. Russo A.A. (1998), Structural basis for inhibition of the cyclin - dependent kinase Cdk6 by the tumour suppressor p16INK4, J. Nature, 395(6699), pp. 237 - 243

[55]. Serizawa H. (1998), Cyclin - dependent kinase inhibitor p16INK4 inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH, J Biol Chem, 273(10), pp. 5427 - 5430. [56]. Sharma G. (2007), Promoter hypermethylation of p16INK4,

p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients, Life Sci, 80(20), pp. 1873 - 1881.

[57]. Sharma S. (2010), Epigenetics in cancer, Carcinogenesis, 31(1), pp. 27 - 36.

[58]. Sherr CJ. (1999), CDK inhibitors: positive and negative regulators of G1 - phase progression, Genes Dev., 13(12), pp. 1501 - 1512

[59]. Shima K. (2011), Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review, Int J Cance, 128(5), pp. 1080 - 1094.

[60]. Shin E. A. (2009), p16INK4 methylation and the correlation to immunohistochemical expression in cervical neoplasia, Journal of Women’s Medicine, 2(1).

[61]. Smith J.R. (1996), Replicative senescence: implications for in vivo aging and tumor suppression, Science, 273(5271), pp. 63 - 67.

[62]. Spathis A. (2011), Promoter Methylation of p16INK4, hMLH1, And MGMT In Liquid - Based cervical cytology samples compared with clinicopathological findings and HPV presence, Infectious Diseases in Obstetrics and Gynecology, ID 927861, pp. 1 - 5.

Lý Th Tuy t Ng c Trang 68 [63]. Szalmas A. (2009), Epigenetic alterations in cervical

carcinogenesis, Semin Cancer Biol, 19(3), pp. 144 - 52.

[64]. Szyf M., (2008), The role of DNA hypermethylation and demethylation in cancer and cancer therapy, Current Oncology, 15(2), pp. 72 - 75.

[65]. Tsao H. (1998), Novel mutations in the p16/CDKN2A binding region of the cyclin - dependent kinase - 4 gene, Cancer Res, 58(1), pp. 109 - 113.

[66]. Vallian S. (2009), Methylation status of p16INK4 tumor suppressor gene in Iranian patients with sporadic breast cancer, Journal of Cancer Research and Clinical Oncology, 135(8), pp. 991 - 996.

[67]. Veganzones - de - Castro S. (2012), p16 gene methylation in colorectal cancer patients with long - term follow - up, Reveso Ennferm Dig, 104(3), pp: 111 - 117

[68]. Vinci D. A. (2005), p16INK4 promoter methylation and protein expression in breast fibroadenoma, International Journal of Cancer, 114, pp. 414 - 421.

[69]. Voyatzi S. (2010), Promoter methylation of p16INK4, RASSF1A, and RAR2 genes in tumor DNA from patients with breast cancer (BC) in correlation with clinical recurrence, Journal finical Oncology, 28(15), 1551.

[70]. Walkley C.R. (2006), Rb is dispensable for self - renewal and multilineage differentiation of adult hematopoietic stem cells, Proc Natl Acad Sci U S A, 103(24), pp. 9057 - 9062.

[71]. Yang H.J. (2004), Detection of hypermethylated genes in tumor and plasma of cervical cancer patients, Gynecologic Oncology, 93, pp. 435 - 440.

[72]. Yang L. (2006), Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never - smoking lung cancer

Lý Th Tuy t Ng c Trang 69 patients, Neoplasia, 8(1), pp. 46 - 51.

[73]. Yoruker E.E. (2012), Promoter and histone methylation and p16 gene expression in colon cancer, Experimental and therapeutic medicine ,4(5), pp. 865 - 870.

[74]. Zhao Y. F. (2010), Methylation and expression of gene p16INK4and RB in breast carcinoma, NCBI, 39(6), pp. 377 - 381.

[75]. Frederique M. (2001), Selective association of the methyl - CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia , 98(9), pp. 4990 - 4995.

[76]. Yakov C. (2005), Melanoma genetics and the development of rational therapeutics, The Journal of Clinical Investigation, 115: pp. 813 ậ 824.

Một phần của tài liệu KHẢO SÁT TÌNH TRẠNG METHYL HÓA GEN p76/XK“2 TẠI CÁC ĐẢO CpG THUỘC VÙNG PROMOTER TRÊN MỘT SÓ BỆNH UNG THƯ (Trang 69 - 84)

Tải bản đầy đủ (PDF)

(84 trang)